Trade Secret Strategy Might Look Better After Myriad Genetics

The recent Supreme Court decision disallowing patents on “genes and the information they encode … simply because they have been isolated from the surrounding genetic material” could make companies working in molecular biology consider eschewing patents in favor of a trade secret strategy. The writer explains last week’s decision in Association for Molecular Pathology v. Myriad Genetics, and why that could be one outcome.